Artiva Biotherapeutics, Inc. (ARTV)
10.22
-0.20
(-1.92%)
USD |
NASDAQ |
Sep 11, 16:00
10.23
+0.01
(+0.10%)
After-Hours: 20:00
Artiva Biotherapeutics Debt to Equity Ratio : 0.0283 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0283 |
| March 31, 2026 | 0.1168 |
| December 31, 2025 | 0.0995 |
| September 30, 2025 | 0.0905 |
| June 30, 2025 | 0.0887 |
| March 31, 2025 | 0.0829 |
| December 31, 2024 | 0.0769 |
| September 30, 2024 | 0.0745 |
| June 30, 2024 | 0.6227 |
| Date | Value |
|---|---|
| March 31, 2024 | 0.3895 |
| December 31, 2023 | 0.3109 |
| September 30, 2023 | |
| March 31, 2023 | |
| March 31, 2022 | 0.0145 |
| December 31, 2021 | 0.0136 |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Climb Bio, Inc. | 0.0055 |
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 368.63M |
| Total Liabilities (Quarterly) | 21.13M |
| Shareholders Equity (Quarterly) | 347.50M |
| Current Ratio | 24.16 |
| Net Debt Paydown Yield | 0.18% |